Systems and methods for deploying an implantable medical electrical lead

Information

  • Patent Grant
  • 11766273
  • Patent Number
    11,766,273
  • Date Filed
    Wednesday, July 22, 2020
    3 years ago
  • Date Issued
    Tuesday, September 26, 2023
    7 months ago
Abstract
A reservoir of a system for deploying an implantable lead to an extravascular location delivers a flow of fluid through a lumen of one or both of a tunneling tool and an introducer of the system. In some cases, the tunneling tool includes a pressure sensor assembly for monitoring a change in a pressure of the flow through the lumen thereof. Alternately, or in addition, a flow-controlled passageway, through which the flow of fluid from the reservoir is delivered to the lumen of the introducer, includes a compliant chamber to hold a reserve of the fluid. Fluid from the reserve may be drawn into the lumen of the introducer as the tunneling tool is withdrawn therefrom. Alternately, the introducer may include a chamber located between two seals, wherein fluid that fills the chamber is drawn distally into the lumen of the introducer, as the tunneling tool is withdrawn therefrom.
Description
TECHNICAL FIELD

The present disclosure is related to implantable medical electrical leads, and more particularly pertains to systems and methods for the deployment thereof.


BACKGROUND

Implantable cardiac defibrillator (ICD) systems are used to delivery high energy electrical pulses or shocks to a patient's heart to terminate life-threatening arrhythmias, such as ventricular fibrillation. Traditional ICD systems include an ICD device and one or more implantable medical electrical leads connected thereto; the device, which has a hermitically sealed housing that encloses a pulse generator and other electronics thereof, is implanted subcutaneously in the chest of the patient, and the leads, referred to herein as transvenous leads, are implanted within the heart.


Traditional ICD systems that utilize transvenous leads may not be preferred for all patients, such as those in whom difficult vascular access precludes the placement of transvenous leads. Moreover, transvenous leads may become fibrosed in the heart over time, making lead revision and extraction procedures challenging. Thus, for some patients, an extravascular ICD system may be preferred, in which a lead (or leads) are implanted in an extravascular location, that is, outside the vascular system of the patient, rather than within the vascular system, for example, in a subcutaneous, sub-sternal, or other extravascular location.


SUMMARY

Embodiments and methods of the present invention, which are disclosed herein, address some difficulties caused when creating tunnels in extravascular locations, for example, within a subcutaneous or sub-sternal space, to which medical electrical leads are deployed for implant. Some specific difficulties are described below, in the Detailed Description section.


According to some embodiments, a tunneling tool of a system for deploying an implantable medical electrical lead to an extravascular location, for example, a sub-sternal space in a body of a patient, has a lumen extending along a length of a shaft of the tool and a pressure sensor assembly mounted in a handle of the tool. The system further includes a fluid supply assembly with a flow-controlled passageway, which, when coupled to a port of the tunneling tool handle, delivers a flow of fluid through the tunneling tool lumen, for example, while an operator employs the tool to create a tunnel within the aforementioned space. According to some methods of the present invention, the operator can monitor, via a display of the pressure sensor assembly, a change in a pressure of the flow, as measured by a pressure transducer of the pressure sensor assembly.


Alternately, or in addition, the fluid supply assembly of some embodiments of the present invention includes a flow-controlled passageway having a compliant chamber, which may be coupled to a port of an introducer to deliver flow of fluid through a lumen of the introducer which is snuggly fitted around a shaft of a tunneling tool, either a standard tunneling tool or one like that described above. According to some methods, the flow-controlled passageway is filled with fluid and the compliant chamber located at an elevation lower than that of the tunnel created by the tunneling tool, so that when the operator withdraws the shaft of the tunneling tool from the lumen of the introducer, after creating the tunnel within the sub-sternal space, fluid from a reserve of fluid filling the compliant chamber is drawn into the lumen of the introducer.


According to some additional embodiments, an introducer of a system for deploying an implantable medical electrical lead to an extravascular location, for example, a sub-sternal space in a body of a patient, has a hub that includes a distal seal and a proximal seal; and a lumen of the introducer, which extends from a proximal opening thereof, formed by the proximal seal, to a distal opening thereof, at a tapered distal end of a tubular member of the introducer, includes a chamber located between the seals of the hub. The introducer hub further includes first, second, and third ports, each of which is in fluid communication with the chamber, wherein the third port is configured to accommodate a standing column of fluid from the chamber, for example, being supplied from a flow-controlled passageway of a fluid supply assembly of the system that is coupled to the second port of the introducer hub to fill the chamber with fluid. The lumen of the introducer may be snuggly fitted around a shaft of a tunneling tool; and, as the tunneling tool shaft is withdrawn out through the proximal opening of the lumen, fluid that fills the chamber of the introducer hub is drawn distally through the distal seal of the introducer hub and into the lumen that extends within the tubular member.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of particular embodiments and do not limit the scope of the disclosure. The drawings are not to scale (unless so stated) and are intended for use in conjunction with the explanations in the following detailed description. Embodiments will hereinafter be described in conjunction with the appended drawings wherein like numerals/letters denote like elements, and:



FIG. 1A is a front view of an exemplary extravascular ICD system implanted within a patient;



FIG. 1B is a side view of the implanted ICD system;



FIG. 1C is a transverse view of the implanted ICD system;



FIG. 2 is a schematic depicting an exemplary tunneling path for forming a tunnel within a sub-sternal space to which an implantable medical electrical lead may be deployed for implant;



FIG. 3 is a plan view that includes partial cross-sections of a system for deploying a medical electrical lead, for example, to the sub-sternal space of FIG. 2, according to some embodiments;



FIG. 4 is a plan view of another system, according some alternate embodiments; and



FIG. 5 is a longitudinal cross-section view of an introducer which may be employed by a system, according to some additional embodiments.





DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of inventive embodiments disclosed herein in any way. Rather, the following description provides practical examples, and those skilled in the art will recognize that some of the examples may have suitable alternatives. Examples of constructions, materials, dimensions and fabrication processes are provided for select elements and all other elements employ that which is known by those skilled in the art.



FIGS. 1A-C are conceptual diagrams of an exemplary extravascular ICD system 10 implanted within a patient 12. Although FIGS. 1A-C are described in the context of cardioversion and cardiac defibrillation therapy, systems and methods for deploying an implantable medical electrical lead, according to the instant disclosure, may be employed for implantable medical devices configured to provide other types of cardiac therapy. FIG. 1A illustrates system 10 including an implantable ICD device 14 and an implantable medical electrical lead 16, which is coupled thereto, wherein ICD device 14 is shown implanted subcutaneously on the left mid-axillary of patient 12, superficially of the patient's ribcage. ICD device 14 includes a hermetically sealed housing in which a pulse generator and other electronics are contained, and which may be formed from a conductive material, such as titanium, or from a combination of conductive and non-conductive materials, wherein the conductive material of housing may be employed as an electrode, for example, to provide cardiac defibrillation therapy in conjunction with a defibrillation electrode 24 of lead 16. ICD device may also include a connector header attached to the housing by which lead 16 is electrically coupled to the electronics contained therein, for example, by electrical contacts contained within the header and a corresponding hermetically sealed feedthrough assembly, such as is known in the art.



FIGS. 1A-B further illustrate lead 16 including an elongate body extending from a proximal connector assembly, which is coupled to the aforementioned connector header of ICD device 14 to a distal portion, about which electrodes 24, 28 and 30 are mounted, wherein each electrode 24, 28, 30 is coupled to a corresponding connector of the connector assembly by an elongate conductor extending within the body of lead 16. Lead 16 extends subcutaneously from ICD device 14, superficial to the ribcage, and toward a center of the torso of patient 12. At a location near the center of the torso, e.g., in proximity to a xiphoid process 20 of the patient's sternum 13, lead 16 bends or turns in a superior direction, and extends under/below sternum 13 within the patient's anterior mediastinum 3, which is best seen in FIG. 1C, so that electrodes 24, 28, 30 are located in proximity to the patient's heart 6.


With reference to FIG. 1C, the anterior mediastinum 3 may be viewed as being bounded laterally by pleurae 39 that enclose the patient's lungs, posteriorly by pericardium 15 that encloses the patient's heart 6, and anteriorly by the sternum 13. In some instances, the anterior wall of the anterior mediastinum 3 may also be formed by the transversus thoracis and one or more costal cartilages. The anterior mediastinum 3 includes a quantity of loose connective tissue (such as areolar tissue), some lymph vessels, lymph glands, sub-sternal musculature (e.g., transverse thoracic muscle), branches of the internal thoracic artery, and the internal thoracic vein. In one example, the distal portion of lead 16 may be implanted substantially within the loose connective tissue and/or sub-sternal musculature of the anterior mediastinum 3. Systems and methods described herein may be used to deploy lead 16 to this extravascular location, however, according to alternate embodiments, the distal portion of lead 16 may be implanted in other non-vascular, extra-pericardial locations, for example, anywhere within a sub-sternal space defined by the undersurface of the sternum 13 and/or ribcage and the pericardium or other portion of heart 6. The sub-sternal space may alternatively be referred to by the terms “retrosternal space” or “mediastinum” or “infrasternal” as is known to those skilled in the art and includes the anterior mediastinum 3. The sub-sternal space may also include the anatomical region described in Baudoin, Y. P., et al., entitled “The superior epigastric artery does not pass through Larrey's space (trigonum sternocostale).” Surg. Radiol. Anat. 25.3-4 (2003): 259-62. In other words, the distal portion of lead 16 may be implanted in the region around the outer surface of heart 6, but not attached to heart 6.



FIG. 2 shows an exemplary sub-sternal path (dashed lines) along which an operator may insert a shaft of a tunneling tool, that is, any tool suited to create an elongate space or tunnel within a body of a patient to receive deployment of an implantable medical electrical lead therein. When inserting the tunneling tool along the path of FIG. 2 (dashed line) and through the above-described sub-sternal tissue, care must be taken by the operator not to perforate through sub-sternal structures or into the chest cavity, which could compromise the pleura 39 of the lungs or the heart 6. The operator must also take care not to draw air into the sub-sternal space when withdrawing the tunneling tool therefrom, to make way for insertion of the medical electrical lead therein, since drawn in air may form pockets around electrodes of the subsequently inserted lead, thereby impacting initial electrode function, for example, by increasing cardiac pacing thresholds and/or impedance and/or cardiac defibrillation thresholds. FIGS. 3 and 4 are plan views of a system 200 and a system 500, respectively, each for deploying a medical electrical lead, according to some alternate embodiments that address these difficulties.



FIG. 3 illustrates system 200 including a tunneling tool 230, which has an elongate and relatively rigid shaft 236. Shaft 236 may be formed from any of a number of medical grade materials, including but not limited to stainless steel. In an exemplary embodiment, shaft has a diameter of approximately 3 millimeters and a length of approximately 30 centimeters, however, shaft 236 may have a smaller or greater diameter and length. Shaft 236, which has a constant stiffness along an entire length thereof, is shown including a blunt distal tip 362 and a lumen 36 extending from a proximal opening thereof (not shown) to a distal opening 302 thereof at distal tip 362. A handle 231 of tunneling tool 230, to which a proximal end 361 of shaft 236 is secured, is shown including a port 310, which is in fluid communication with shaft lumen 36, and a pressure sensor assembly 316 mounted therein. FIG. 3 further illustrates system 200 including a fluid supply assembly, which includes a fluid reservoir 210, for example, filled with a saline solution, and at least one passageway 211 coupled thereto. Passageway 211 is configured for coupling to port 310 of tunneling tool 230, for example, via connection of a luer fitting 215 thereof to a stopcock type valve connector 21 of port 310. Fluid from reservoir 210 flows through passageway 211, for example, being driven by a pressure head created by an elevation of reservoir 210, and is shown being flow-controlled by a clip-type flow restrictor 20.


According to the illustrated embodiment, port 310 of tunneling tool 230 is in fluid communication with lumen 36 of tunneling tool 230, as is a pressure transducer/gauge (not shown) of pressure sensor assembly 316. Thus, when flow-controlled passageway 211 is coupled to port 310, fluid may flow from reservoir 210 and through tunneling tool lumen 36 while a change in pressure of the flow is measured by the pressure transducer. FIG. 3 illustrates pressure sensor assembly 316 including a display 31 conveniently located on handle 231 so that, as the operator is using tunneling tool 230 to create a tunnel within the sub-sternal space, for example, by inserting shaft 236 along the path of FIG. 2, the operator can view display 31 to monitor pressure changes in the flow of fluid through shaft lumen 36, as influenced by the insertion of shaft 236 along the path, thereby gaining some feedback concerning whether or not distal tip 362 has perforated into another bodily cavity. According to some exemplary embodiments, the pressure transducer/gauge may be specified in accordance with the following:


Continuous Flow Rate: 3 cc/hr (±1 cc/hr) or 30 cc/hr (±10 cc/hr) at 300 mmHg


Operating Pressure Range: −50 to +300 mmHg


Sensitivity: 5 μV/V/mmHg, ±2% (typically <±1%)


Overpressure Protection: −400 to +4000 mmHg


Operating Temperature: 15° C. to 40° C.


Operating Life: >500 hours


Storage Temperature: −25° C. to +65° C.


Natural Frequency: >200 Hz in saline


However, the pressure transducer/gauge may have other specifications without departing from the scope of this disclosure.


In some embodiments, lumen 36 of tunneling tool 230 may be used to receive a guide wire (dashed lines of FIG. 3) in sliding engagement therewith. In these embodiments, according to some methods, an operator can advance an atraumatic distal end of the guide wire ahead of distal tip 236 to help estimate whether or not a perforation is likely with further advancement of relatively rigid shaft 236.


With further reference to FIG. 3, system 200 further includes an introducer 240, wherein a lumen 26 defined by a tubular member 246 of introducer 240, is snuggly fitted around tunneling tool shaft 236 for sliding engagement therewith. A wall of tubular member 246 is relatively flexible, for example, being formed from polytetrafluoroethylene (PTFE), Fluorinated ethylene propylene (FEP), or polyether block amide (PEBAX®). A proximal end 461 of tubular member 246 is shown being attached to a proximal terminal hub 241 of introducer 240, which may be formed in part by a relatively rigid plastic, such as PEBAX®; a proximal opening 261 of lumen 26 is formed by hub 241, for example, being defined by a seal within hub 241. The seal within hub 241 may be any suitable type, for example, formed from an elastomeric material such as silicone rubber, which allows passage of an elongate body therethrough, such as tunneling tool shaft 236 or a medical electrical lead, while forming a seal thereabout, one example of which is a slit valve. Lumen 26 extends from proximal opening 261 to a distal opening 262 thereof, at a tapered distal end 462 of tubular member 246. According to the illustrated embodiment, distal end 462 of tubular member 246 tapers down to a diameter that approaches an outer diameter of tunneling tool shaft 236 so that the operator can advance, with relative ease, introducer 240 over shaft 236 and into the sub-sternal space in which shaft 236 is inserted. Once within the space, and after the operator withdraws tunneling tool shaft 236, introducer lumen 26 can serve as a conduit through which the operator may deploy an implantable medical electrical lead to the space, after which the operator may remove introducer 240 from around the deployed lead, for example, by splitting or slitting introducer 240, according to methods known in the art. According to some embodiments, the fluid flow through lumen 36 of tunneling tool shaft 236, via the above-described coupling of port 310 to flow-controlled passageway 211, continues while shaft 236 is withdrawn, and is sufficient to fill the void left behind by shaft 236, so that a vacuum does not draw air into the space. But, in some embodiments, a port 410 of introducer hub 241, which is in fluid communication with introducer lumen 26, can be coupled to another flow-controlled passageway 212 of the fluid supply assembly, for example, via connector 215, as shown in FIG. 4, so that a flow of fluid from reservoir 210 through lumen 26 can supplement that through tunneling tool lumen 36 to fill the void left by the withdrawn tunneling tool shaft 236.



FIG. 4 illustrates system 500 including a standard tunneling tool 330 (e.g., Medtronic® Model 6996T tunneling tool), which is shown engaged within introducer lumen 26 and inserted into the patient's body to create a tunnel within the sub-sternal space, for example, along the path of FIG. 2. A shaft 336 of tunneling tool 330 includes a blunt distal tip 362, like shaft 236 of tool 230, but does not include a lumen; however, according to some alternate embodiments, the above-described tunneling tool 230 may be employed in lieu of tool 330, with flow-controlled passageway 211 coupled to port 310 thereof (FIG. 3). FIG. 4 further illustrates fluid reservoir 210 located at a first elevation E1 and a working plane of tunneling tool 330 located at a second elevation E2, which is lower than first elevation E1. Thus, flow-controlled passageway 212, by means of the pressure head created by elevation E1, provides a steady flow of fluid through introducer lumen 26 via a coupling thereof to port 410 of introducer hub 214 (as would passageway 211 through lumen 36 of tunneling tool 230 via port 310, in alternate embodiments). Port 410, like port 310 of tunneling tool 230, is shown including valve connector 21, to which connector 215 of passageway 212 is coupled. The rate of flow from reservoir 210 and through passageway 212, for example, being controlled by clip 20, is limited to prevent flooding of the path of tunneling tool shaft 336, but, when shaft 336 is withdrawn, this rate of flow may not be rapid enough to fill the vacuum and prevent air from being sucked into the space. Thus, with further reference to FIGS. 3 and 4, flow-controlled passageway 212 includes a compliant chamber 22 to retain a reserve of fluid that flows therethrough from reservoir 210, for example, to function as an accumulator, which is then available to provide more rapid flow, per arrow f, in response to the vacuum created when the operator withdraws tunneling tool 330, per arrow W, for example, by pulling on a proximal portion of shaft 336 that is formed into a handle 331. According to some methods, as shown in FIG. 4, chamber 22 is located at an elevation E3 which is lower than elevation E2, which may be necessary to prevent the reserve of fluid from compliant chamber 22 from draining into the path of tunneling tool shaft 336 before tunneling tool 330 is withdrawn.



FIG. 5 is a longitudinal cross-section view of an introducer 740 which may be employed by a system, according to some additional embodiments, being used in conjunction with either of the above-described tunneling tools 230, 330, or with a standard dilator tool that an operator may use as a tunneling tool. FIG. 5 illustrates introducer 740 including a tubular member 746 and a proximal terminal hub 741 to which a proximal end 661 of tubular member 746 is attached, wherein tubular member 746 defines a lumen 76, and hub 741 includes a proximal seal 601 that defines a proximal opening 761 of lumen 76. Lumen 76 extends from proximal opening 761 to a distal opening 762 thereof, at a tapered distal end 662 of member 746, and includes a chamber 76-C located within hub 741, between proximal seal 601 and a distal seal 602 thereof. Each of seals 601, 602, like the seal of hub 241, described above, may be formed from an elastomeric material and allow passage of an elongate body therethrough while forming a seal thereabout. FIG. 5 further illustrates hub 741 including first, second and third ports 71, 72, 73, all in fluid communication with chamber 76-C, wherein first port 71 may be employed for flushing of chamber 76-C, by opening valve connector 21 thereof, second port 72 is coupled to flow-controlled passageway 211 (e.g., by valve connector 21) so that chamber 76-C may be filled with fluid from reservoir 210, and third port 73 accommodates a standing column of fluid from chamber 76-C, which can act as an accumulator and is open to atmospheric pressure to allow air bubbles to escape. According to the illustrated embodiment, proximal and distal seals 601, 602 function to retain fluid within chamber 76-C and within the standing column of fluid in third port 73, so that the fluid-filled chamber 76-C can prevent air from entering lumen 76 when tubular member 746 is inserted within the sub-sternal space, and when tunneling tool shaft 236/336 is withdrawn out from lumen 76 through proximal opening 761, and when another tool or a lead is inserted into lumen 76 via proximal opening 761 for deployment into the sub-sternal space. In some embodiments, port 73 includes a compliant section (shown with dotted lines), through which the standing column of fluid extends, that can enhance an accumulator function of port 73. Furthermore, hub 741 and tubular member 746 of introducer 740 may be configured to split apart for the removal of introducer 740 from around the deployed lead.


Finally, another difficulty that may be encountered, when employing tunneling procedures to deploy implantable medical electrical leads, is the potential of infecting the sub-sternal space. Thus, according to some embodiments and methods, a saline solution that fills fluid reservoir 210 may be mixed with an antibiotic agent (e.g., Meropenem, Ceftriaxone, Cefazoline, Vancomycin, Clindamycin, Neomycin, Cephalexin, or Levofloxacin Quinolone) to fight infection. Thus, while the operator is inserting tunneling tool shaft 236/336 into a patient's body, for example, along the path of FIG. 1, a flow of the antibiotic laced saline solution may be delivered into the space formed by shaft 236/336, either through lumen 36 of shaft 236 and/or through lumen 26/76 of introducer 240/740.


In the foregoing detailed description, the invention has been described with reference to specific embodiments. However, it may be appreciated that various modifications and changes can be made without departing from the scope of the invention as set forth in the appended claims. For example, the delivery systems and techniques of this disclosure may be used to implant medical electrical leads in subcutaneous paths above the ribcage and/or sternum.

Claims
  • 1. A system comprising: a tunneling tool including an elongate and relatively rigid shaft, a handle, and a pressure sensor assembly mounted in the handle, the shaft having a constant stiffness along an entire length thereof, the shaft including a proximal end secured to the handle, a blunt distal tip, and a lumen extending from a proximal opening thereof, at the proximal end of the shaft, to a distal opening thereof, at the distal tip of the shaft, the handle including a port in fluid communication with the lumen, and the pressure sensor assembly including a pressure transducer, in fluid communication with the lumen, configured to measure a change in a pressure of a flow of fluid from a fluid reservoir, and a display coupled to the transducer;an introducer including a tubular member and a proximal terminal hub, the tubular member including a proximal end attached to the hub and a tapered distal end, and the tubular member defining a lumen, the lumen of the introducer extending from a proximal opening thereof, formed by the hub, to a distal opening thereof, at the tapered distal end of the tubular member, the lumen of the introducer being snuggly fitted around the shaft of the tunneling tool for sliding engagement therewith, and the lumen of the introducer being sized for sliding engagement of an implantable lead therein, after the shaft of the tunneling tool is withdrawn from engagement therewith; anda fluid supply assembly including the fluid reservoir, at least one flow-controlled passageway coupled to the reservoir to accommodate the flow of fluid from the reservoir therethrough, and one of the at least one flow-controlled passageway, being configured for coupling to the port of the handle of the tunneling tool; andwherein, when a first passageway of the at least one flow-controlled passageway of the fluid supply assembly is coupled to the port of the handle of the tunneling tool, fluid from the reservoir flows through the first passageway and through the lumen of the tunneling tool, and the change in a pressure of the flow, as measured by the pressure transducer of the pressure sensor assembly, is presented on the display of the pressure sensor assembly, andthe first passageway of the at least one flow-controlled passageway of the fluid supply assembly includes a compliant chamber for retaining a reserve of fluid that flows therethrough.
  • 2. The system of claim 1, further comprising a guide wire, the lumen of the tunneling tool being sized for sliding engagement of the guide wire therein.
  • 3. The system of claim 1, wherein the fluid in the fluid reservoir of the fluid supply assembly comprises a saline solution mixed with an antibiotic agent.
  • 4. The system of claim 1, wherein the display is located on the handle of the tunneling tool.
  • 5. The system of claim 1, wherein the flow of the fluid from the reservoir through the first passageway and through the lumen of the tunneling tool is configured to be driven by a pressure head created by an elevation of the reservoir relative to the tunneling tool.
  • 6. The system of claim 1, wherein the change in a pressure of the flow of the fluid is influenced by the insertion of the shaft of the tunneling tool in a substernal space of the body of the patient.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 14/935,708, filed Nov. 9, 2015, entitled “SYSTEMS AND METHODS FOR DEPLOYING AN IMPLANTABLE MEDICAL ELECTRICAL LEAD,” which claims the benefit of U.S. Provisional Patent Application No. 62/093,496, filed Dec. 18, 2014, entitled “SYSTEMS AND METHODS FOR DEPLOYING AN IMPLANTABLE MEDICAL ELECTRICAL LEAD.” The entire content of each of these applications is incorporated by reference herein.

US Referenced Citations (180)
Number Name Date Kind
3496932 Prisk et al. Feb 1970 A
4030509 Heilman et al. Jun 1977 A
4146037 Flynn et al. Mar 1979 A
4270549 Heilman Jun 1981 A
4280510 O'Neill Jul 1981 A
4291707 Heilman et al. Sep 1981 A
4419095 Nebergall et al. Dec 1983 A
4437475 White Mar 1984 A
4512351 Pohndorf Apr 1985 A
4538624 Tarjan Sep 1985 A
4552157 Littleford Nov 1985 A
4664113 Frisbie et al. May 1987 A
4765341 Mower et al. Aug 1988 A
4832687 Smith, III May 1989 A
5036854 Schollmeyer et al. Aug 1991 A
5125904 Lee Jun 1992 A
5176135 Fain et al. Jan 1993 A
5190529 McCrory et al. Mar 1993 A
5224934 Payne et al. Jul 1993 A
5255691 Otten Oct 1993 A
5255692 Neubauer et al. Oct 1993 A
5300106 Dahl et al. Apr 1994 A
5312355 Lee May 1994 A
5441504 Pohndorf et al. Aug 1995 A
5456699 Armstrong Oct 1995 A
5505707 Manzie et al. Apr 1996 A
5509924 Paspa et al. Apr 1996 A
5613953 Pohndorf Mar 1997 A
5690648 Fogarty et al. Nov 1997 A
5782239 Webster, Jr. Jul 1998 A
5951518 Licata et al. Apr 1999 A
5944732 Raulerson et al. Aug 1999 A
6032079 KenKnight et al. Feb 2000 A
6059750 Fogarty et al. May 2000 A
6104957 Ala et al. Aug 2000 A
6122552 Tockman et al. Sep 2000 A
6159198 Gardeski et al. Dec 2000 A
6228052 Pohndorf May 2001 B1
6267747 Samson et al. Jul 2001 B1
6277107 Lurie et al. Aug 2001 B1
6324414 Gibbons et al. Nov 2001 B1
6415187 Kuzma et al. Jul 2002 B1
6445954 Olive et al. Sep 2002 B1
6511434 Haytman et al. Jan 2003 B1
6544247 Gardeski et al. Apr 2003 B1
6591129 Ben-Haim et al. Jul 2003 B1
6730083 Freigang et al. May 2004 B2
6733500 Kelley et al. May 2004 B2
6749574 O'Keefe Jun 2004 B2
6770070 Balbierz Aug 2004 B1
6772014 Coe et al. Aug 2004 B2
6836687 Kelley et al. Dec 2004 B2
6866044 Bardy et al. Mar 2005 B2
6868291 Bonner et al. Mar 2005 B1
6887229 Kurth May 2005 B1
6890295 Michels et al. May 2005 B2
6892087 Osypka May 2005 B2
6921396 Wilson et al. Jul 2005 B1
7033326 Pianca et al. Apr 2006 B1
7069083 Finch et al. Jun 2006 B2
7117039 Manning et al. Oct 2006 B2
7158838 Seifert et al. Jan 2007 B2
7192433 Osypka et al. Mar 2007 B2
7195637 Mika Mar 2007 B2
7218970 Ley et al. May 2007 B2
7229450 Chitre et al. Jun 2007 B1
7288096 Chin Oct 2007 B2
7316667 Lindstrom et al. Jan 2008 B2
7322960 Yamamoto et al. Jan 2008 B2
7369899 Malinowski et al. May 2008 B2
7389134 Karicherla et al. Jun 2008 B1
7450997 Pianca et al. Nov 2008 B1
7497844 Spear et al. Mar 2009 B2
7499758 Cates et al. Mar 2009 B2
7539542 Malinowski May 2009 B1
7627375 Bardy et al. Dec 2009 B2
7655014 Ko et al. Feb 2010 B2
7736330 Bardy Jun 2010 B2
7765014 Eversull et al. Jul 2010 B2
7801622 Camps et al. Sep 2010 B2
7815604 Massengale et al. Oct 2010 B2
7837671 Eversull et al. Nov 2010 B2
7846088 Ness Dec 2010 B2
7850610 Ferek-Petric Dec 2010 B2
7930040 Kelsch et al. Apr 2011 B1
7983765 Doan et al. Jul 2011 B1
8060207 Wallace et al. Nov 2011 B2
8065020 Ley et al. Nov 2011 B2
8066702 Rittman, III et al. Nov 2011 B2
8083728 Rome Dec 2011 B2
8090451 Tyson, Jr. Jan 2012 B2
8155755 Flynn et al. Apr 2012 B2
8157813 Ko et al. Apr 2012 B2
8260436 Gerber et al. Sep 2012 B2
8280527 Eckerdal et al. Oct 2012 B2
8328738 Frankhouser et al. Dec 2012 B2
8340779 Harris et al. Dec 2012 B2
8355786 Malinowski Jan 2013 B2
8386052 Harris et al. Feb 2013 B2
8394079 Drake et al. Mar 2013 B2
8435208 Bardy May 2013 B2
8442620 Silipo et al. May 2013 B2
8452421 Thenuwara et al. May 2013 B2
8478424 Tronnes Jul 2013 B2
8478426 Barker Jul 2013 B2
8886311 Anderson et al. Nov 2014 B2
20020120294 Kroll Aug 2002 A1
20030114908 Flach Jun 2003 A1
20040030333 Goble Feb 2004 A1
20040059348 Geske et al. Mar 2004 A1
20040102829 Bonner et al. May 2004 A1
20040210293 Bardy et al. Oct 2004 A1
20040236396 Coe et al. Nov 2004 A1
20050049663 Harris et al. Mar 2005 A1
20050131505 Yokoyama Jun 2005 A1
20050288758 Jones et al. Dec 2005 A1
20050288759 Jones et al. Dec 2005 A1
20060041295 Okypka Feb 2006 A1
20060116746 Chin Jun 2006 A1
20060122676 Ko et al. Jun 2006 A1
20060253181 Schulman et al. Nov 2006 A1
20070023947 Ludwig et al. Feb 2007 A1
20070055204 Geisler et al. Mar 2007 A1
20070191781 Richards et al. Apr 2007 A1
20070100409 Worley et al. May 2007 A1
20070173900 Siegel et al. Jul 2007 A1
20070179388 Larik et al. Aug 2007 A1
20070208402 Helland et al. Sep 2007 A1
20070249992 Bardy Oct 2007 A1
20080046056 O'Connor Feb 2008 A1
20080243219 Malinowski et al. Oct 2008 A1
20080249501 Yamasaki Oct 2008 A1
20080269716 Bonde et al. Oct 2008 A1
20080269763 Bonde et al. Oct 2008 A1
20090076476 Barbagli et al. Mar 2009 A1
20090157091 Buysman Jun 2009 A1
20090222021 Chang et al. Sep 2009 A1
20090259283 Brandl et al. Oct 2009 A1
20090264780 Schilling Oct 2009 A1
20100010442 Shivkumar et al. Jan 2010 A1
20100016935 Strandberg et al. Jan 2010 A1
20100030227 Kast et al. Feb 2010 A1
20100030228 Havel Feb 2010 A1
20100056858 Mokelke et al. Mar 2010 A1
20100094252 Wengreen et al. Apr 2010 A1
20100113963 Smits et al. May 2010 A1
20100125194 Bonner et al. May 2010 A1
20100137879 Ko et al. Jun 2010 A1
20100152747 Padiy et al. Jun 2010 A1
20100179562 Linker et al. Jul 2010 A1
20100217298 Bardy et al. Aug 2010 A1
20100217301 Bardy et al. Aug 2010 A1
20100249696 Bardy et al. Sep 2010 A1
20100262158 Siegel et al. Oct 2010 A1
20100305428 Bonner et al. Dec 2010 A1
20100318098 Lund et al. Dec 2010 A1
20100331854 Greenberg Dec 2010 A1
20110009933 Barker et al. Jan 2011 A1
20110224680 Barker et al. Sep 2011 A1
20110224681 McDonald Sep 2011 A1
20110230906 Modesitt et al. Sep 2011 A1
20110257660 Jones et al. Oct 2011 A1
20120016377 Geroy Jan 2012 A1
20120029335 Sudam et al. Feb 2012 A1
20120078266 Tyson, Jr. Mar 2012 A1
20120089153 Christopherson et al. Apr 2012 A1
20120097174 Spotnitz et al. Apr 2012 A1
20120191106 Ko et al. Jul 2012 A1
20120209283 Zhu et al. Aug 2012 A1
20120209285 Barker et al. Aug 2012 A1
20120215218 Lipani Aug 2012 A1
20120220894 Melsheimer Aug 2012 A1
20130066331 Chitre et al. Mar 2013 A1
20130103049 Bonde Apr 2013 A1
20130158564 Harris et al. Jun 2013 A1
20130238067 Baudino et al. Sep 2013 A1
20140330208 Christie et al. Nov 2014 A1
20140330248 Thompson-Nauman et al. Nov 2014 A1
20160067446 Klenk Mar 2016 A1
20160175584 Drake et al. Jun 2016 A1
Foreign Referenced Citations (6)
Number Date Country
101072601 Nov 2007 CN
0517494 Dec 1992 EP
1634615 Mar 2006 EP
2001023035 Apr 2001 WO
2004073506 Sep 2004 WO
2012159000 Nov 2012 WO
Non-Patent Literature Citations (40)
Entry
Final Office Action from U.S. Appl. No. 14/257,519, dated Aug. 3, 2020, 19 pp.
Amendment in Response to Office Action dated Aug. 3, 2020, from U.S. Appl. No. 14/257,519, filed Oct. 2, 2020, 7 pp.
Notice of Allowance from U.S. Appl. No. 14/257,519, dated Oct. 28, 2020, 9 pp.
U.S. Appl. No. 17/188,538, filed Mar. 1, 2021, by Christie et al.
Medtronic, Inc., 6996SQ Subcutaneous, Unipolar Lead with Defibrillation Coil Electrode, Technical Manual, 22 pages, (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 1997, is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue.) 1997.
Medtronic, Inc., 6996T Tunneling Tool, Technical manual, 12 pages. (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 1997, is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue.) 1997.
Greatbatch Medical, OptiSeal Valved Peelable Introducer Brochure, 2 pages, (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2010, is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue.) 2010.
Haydin et al., “Subxiphoid Approach to Epicardial Implantation of Implantable Cardioverter Defibrillators in Children”, PACE, vol. 36, Aug. 2013, 6 pp.
Avogadros Lab Supply Inc., Catalog; Scoopula with Beech Wood Handle, can be found on-line at http://www.avogadro-lab-supply.com/search.php, accessed Feb. 18, 2014, 1 page.
Baudoin et al., “The Superior Epigastric Artery Does Not Pass Through Larrey's Space (Trigonum Sternocostale),” Surg Radiol Anat, vol. 25, Aug. 1, 2003, 4 pp.
Bielefeld et al., “Thoracoscopic Placement of Implantable Cardioverter-Defibrillator Patch Leads in Sheep”, Circulation, vol. 88, Park 2, Nov. 1993, 5 pp.
Bolling et al., “Automatic Internal Cardioverter Defibrillator: A Bridge to Heart Transplantation”, Heart Lung Transplantation, Abstract Only, Jul.-Aug. 1991, 1 page.
Cigna et al., “A New Technique for Substernal Colon Transposition with A Breast Dissector: Report of 39 Cases” Elsevier, JPRAS, An International Journal of Surgical Reconstruction, Journal of Plastic, Reconstructive & Aesthetic Surgery, vol. 59, Sep. 24, 2005, 4 pp.
Damiano, “Implantation of Cardioverter Defibrillators in the Post-Sternotomy Patient”, The Annals of Thoracic Surgery, vol. 53, Presented at the Thirty-eighth Annual Meeting of the Southern Thoracic Surgical Association, Nov. 7-9, 1992, pp. 978-983.
Ely et al., “Thoracoscopic Implantation of the Implantable Cardioverter Defibrillator”, Minimally Invasive Techniques, Chest, vol. 103, Issue 1, (Can be found on the World-Wide Web at http://chestioumal.chestpubs.org on May 6, 2013), dated Jan. 1993; 2 pp.
Frame et al., “Long-Term Stability of Defibrillation Thresholds with Intrapericardial Defibrillator Patches”, Deparments of Cardiothoracic Surgery and medicine, Montefiore Medical Center, Pace, vol. 16, Jan. 1993, 6 pp.
Ganapathy et al., “Implantable Device to Monitor Cardiac Activity with Sternal Wires,” Pace—Pacing and Clinical Electrophysiology, Official Journal of the World Society of Arhythmias, vol. 37, Issue 12, Dec. 2014, 11 pp.
Guenther et al., “Substernal Lead Implantation: A Novel Option to Manage OFT Failure in S-ICD patients,” Springer, Clinical Research Cardiology, vol. 104, Oct. 2, 2014, 3 pp.
Harman et al., “Differences in the Pathological Changes in Dogs' Hearts After Defibrillation with Extrapericardial Paddles and Implanted Defibrillator Electrodes”, Journal of Pacing and Clinical Electrophysiology, Pace, vol. 14, Part 2, Feb. 1991, 5 pp.
Karwande et al.,“Bilateral Anterior Thoracotomy for Automatic Implantable Cardioverter Defibrillator Placement in Patients with Previous Sternotomy,” The Society of Thoracic Surgeons, The Annals of Thoracic Surgery, vol. 54, Oct. 1992, 3 pp.
Lawrie et al., “Right Mini-Thoracotomy: An Adjunct to Left Subcostal Automatic Implantable Cardioverter Defibrillator Implantation,” The Society of Thoracic Surgeons, The Annals of Thoracic Surgery, vol. 47, Nov. 18, 1989, 4 pp.
Lemmer, “Defibrillator Patch Constriction, Letter to the Editor,” The Annals of Thoracic Surgery, vol. 61, Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 1996, is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue.), 1 pp.
Mitchell et al., “Experience with an Implantable Tiered Therapy Device Incorporating Antitachycardia Pacing and Cardioverter/Defibrillator Therapy,” Thoracic and Cardiovascular Surgery, Abstract Only, Mar. 1993, 1 pp.
Molina et al., “An Epicardial Subxiphoid Implantable Defibrillator Lead: Superior Effectiveness After Failure of Standard Implants”, From the Department of Surgery, Division of Cardiovascular and Thoracic Surgery and the Department of Medicine, Cardiac Arrhymthmia Center, University of Minnesota Medical School, Minneapolis, Minnesota, Pace, vol. 27, Nov. 2004, 7 pp.
Obadia et al., “Thoracoscopic Approach to Implantable Cardioverter Defibrillator Patch Electrode Implantation,” Pace, Pacing and Clinical Electrophysiology, vol. 19, Jun. 1996, 6 pp.
Obadia et al., “New Approach for Implantation of Automatic Defibrillators Using Videothoracoscopy,” Journal Ann Cardiol Angeiol (Paris), vol. 43, Issue 7, Sep. 1994, Abstract Only, 1 pp.
Pebax Product Brochure, 14 pages and can be found on-line at http://www.pebax.com/export/sites/pebax/content/medias/downloads/literature/pebax-product-rang-brouchure.pdf, accessed on Feb. 28, 2014, 14 pp.
Piccione, et al., “Erosion of Extrapericardiallmplantable Cardioverter Defibrillator Patch Through the Gastic Fundus with Fistulous Tract Information”, Cardiology in Review, vol. 14, No. 6, Nov./Dec. 2006, 3 pp.
Quigley et al., “Migration of an Automatic Implantable Cardioverter-Defibrillator Patch Causing Massive Hemothorax”, Journal Texas Heart Institute, vol. 23, Nov. 1, 1996, 4 pages.
Shapira et al., A Simplified Method for Implantation of Automatic Cardioverter Defibrillator in Patients with Previous Cardiac Surgery, Pace, Pacing and Clinical Electrophysiology, vol. 16, Part 1, Jan. 1993, 6 pp.
Steinke et al., Subepicardial Infarction, Myocardial Impression, and Ventricular Penetration by Sutureless Electrode and Leads, Chest, vol. 70, Issue 1, Jul. 1976, 2 pp.
Substernal Medical Definition, Copyright 2019 Merriam-Webster, Incorporated, accessed fromhttps://www.merriam-webster.com/medical/substernal, accessed on Oct. 3, 2019, 1 pp.
Tung et al., “Initial Experience of Minimal Invasive Extra Cardiac Placement of High Voltage Defibrillator Leads,” Canadian Cardiovascular Congress 2007, vol. 23, Oct. 2007, 4 pp.
Tung et al., “Minimal Invasive Extra Cardiac Placement of High Voltage Defibrillator Leads”, Poster 3; S200 Abstract, P0-3-4; St. Paul Hospital, Vancouver, British Columbia, Canada, Accessed on Aug. 12, 2014, 1 pp.
Vyhmeister et al., “Simple Approach for Extrapericardial Placement of Defibrillator Patches via Median Sternotomy,” The Society of Thoracic Surgeons, The Annals of Thoracic Surgery, vol. 57, Dec. 4, 1994, 4 pp.
Prosecution History from U.S. Appl. No. 14/935,708, dated Oct. 4, 2018 through Jul. 9, 2020, 90 pp.
Prosecution History from U.S. Appl. No. 14/257,519, dated Dec. 4, 2015 through May 5, 2020, 228 pp.
Office Action from U.S. Appl. No. 17/188,538 dated Mar. 9, 2023, 13 pp.
Response to Office Action dated Mar. 9, 2023 from U.S. Appl. No. 17/188,538, filed Jun. 9, 2023, 9 pp.
Notice of Allowance from U.S. Appl. No. 17/188,538 dated Jul. 26, 2023, 11 pp.
Related Publications (1)
Number Date Country
20200345387 A1 Nov 2020 US
Provisional Applications (1)
Number Date Country
62093496 Dec 2014 US
Continuations (1)
Number Date Country
Parent 14935708 Nov 2015 US
Child 16935942 US